Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Latest News about ESALF
Recent news which mentions ESALF
< Previous
1
2
Next >
National Institute on Aging Aims Building $300M Alzheimer's Research Database
April 03, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Government
ESALF
BIIB
From
Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
March 31, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Health Care
Market News
Biotech
From
Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
Tickers
BIIB
ESALF
ESALY
LLY
Tags
ESALY
Benzinga
News
From
Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
March 14, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Health Care
Expert Ideas
General
From
Benzinga
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
March 06, 2023
Tickers
BIIB
ESALF
ESALY
Tags
ESALF
Biotech
Market News
From
Benzinga
The 7 Best Growth Stocks to Buy for February 2023
February 06, 2023
Tickers
ACLS
CPRX
DAR
ESALF
Tags
LSCC
ICLR
PFGC
From
InvestorPlace
New Alzheimer’s drug shows some promise, but has big price tag
February 02, 2023
Tickers
BIIB
ESALF
Tags
JP:4523
BIIB
ESALF
From
MarketWatch
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
January 06, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Trading Ideas
ESALF
Biotech
From
Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
December 22, 2022
Tickers
BIIB
ESALF
ESALY
Tags
BIIB
Biotech
Market News
From
Benzinga
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
December 20, 2022
Tickers
CPRX
ESALF
ESALY
Tags
Market News
Biotech
Small Cap
From
Benzinga
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
November 30, 2022
Tickers
BIIB
ESALF
ESALY
Tags
ESALY
Movers
Benzinga
From
Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
November 30, 2022
Tickers
BIIB
ESALF
ESALY
Tags
ESALF
BIIB
Market News
From
Benzinga
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
November 28, 2022
Tickers
BIIB
ESALF
ESALY
Tags
why it's moving
Health Care
ESALY
From
Benzinga
One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments
November 14, 2022
Tickers
BIIB
ESALF
LLY
MOR
Tags
MOR
JP:4523
BIIB
From
MarketWatch
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
Tickers
BIIB
ESALF
ESALY
MOR
Tags
Health Care
why it's moving
RHHVF
From
Benzinga
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
Tickers
BIIB
ESALF
ESALY
LLY
Tags
RHHBY
LLY
Health Care
From
Benzinga
Medicare coverage of Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
September 28, 2022
Tickers
BIIB
ESALF
SPX
Tags
JP:4523
BIIB
ESALF
From
MarketWatch
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
September 12, 2022
Tickers
ESALF
ESALY
MRK
Tags
ESALF
Biotech
Market News
From
Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
August 25, 2022
Tickers
ESALF
ESALY
LLY
RHHBF
Tags
ESALF
Analyst Ratings
RHHBF
From
Benzinga
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
August 03, 2022
Tickers
ESALF
ESALY
MRK
Tags
ESALF
MRK
Biotech
From
Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
July 06, 2022
Tickers
AMTI
BIIB
ESALF
ESALY
Tags
Benzinga
ESALY
News
From
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Tickers
AGEN
ARWR
ATNX
AVGR
Tags
General
BHVN
XENE
From
Benzinga
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
May 10, 2022
Tickers
BIIB
ESALF
ESALY
Tags
ESALF
Alzheimer's disease
Biotech
From
Benzinga
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
March 22, 2022
Tickers
BIIB
ESALF
ESALY
Tags
Phase 2 Trial
Health Care
ESALY
From
Benzinga
FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer
March 22, 2022
Tickers
ESALF
ESALY
MRK
Tags
News
Briefs
General
From
Benzinga
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
March 15, 2022
Tickers
BIIB
ESALF
ESALY
Tags
General
News
Briefs
From
Benzinga
Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting
February 25, 2022
Tickers
ESALF
ESALY
MRK
Tags
General
Briefs
News
From
Benzinga
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply
January 12, 2022
Tickers
BIIB
ESALF
ESALY
LLY
Tags
General
FDA
Briefs
From
Benzinga
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026
December 16, 2021
Tickers
BIIB
ESALF
ESALY
Tags
Health Care
Briefs
News
From
Benzinga
Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma
November 29, 2021
Tickers
ESALF
ESALY
MRK
Tags
MRK
Health Care
Biotech
From
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.